Structure-based druggability assessment--identifying suitable targets for small molecule therapeutics.
about
Prediction of Druggable Proteins Using Machine Learning and Systems Biology: A Mini-ReviewComputational methods in drug discoveryDelivery of gene silencing agents for breast cancer therapyDissecting Fragment-Based Lead Discovery at the von Hippel-Lindau Protein:Hypoxia Inducible Factor 1α Protein-Protein InterfaceThe crystal structure of Leishmania major N5,N10-methylenetetrahydrofolate dehydrogenase/cyclohydrolase and assessment of a potential drug targetAssessment of Pseudomonas aeruginosa N5,N10-Methylenetetrahydrofolate Dehydrogenase - Cyclohydrolase as a Potential Antibacterial Drug TargetHigh-resolution structure of the M14-type cytosolic carboxypeptidase fromBurkholderia cenocepaciarefined exploitingPDB_REDOstrategiesStructure-based druggability assessment of the mammalian structural proteome with inclusion of light protein flexibilityTo Hit or Not to Hit, That Is the Question - Genome-wide Structure-Based Druggability Predictions for Pseudomonas aeruginosa ProteinsModelling three-dimensional protein structures for applications in drug design.Fractal Dimensions of Macromolecular Structures.Ultra-High-Throughput Structure-Based Virtual Screening for Small-Molecule Inhibitors of Protein-Protein Interactions.Benzene Probes in Molecular Dynamics Simulations Reveal Novel Binding Sites for Ligand Design.Bioengineered vaults: self-assembling protein shell-lipophilic core nanoparticles for drug delivery.SPILLO-PBSS: detecting hidden binding sites within protein 3D-structures through a flexible structure-based approach.Using chiral molecules as an approach to address low-druggability recognition sites.New Frontiers in DruggabilityGenetic Approaches to Facilitate Antibacterial Drug Development.Bioinformatics and variability in drug response: a protein structural perspective.Identification of pharmacological targets in amyotrophic lateral sclerosis through genomic analysis of deregulated genes and pathways.Lessons from Hot Spot Analysis for Fragment-Based Drug Discovery.DARC: Mapping Surface Topography by Ray-Casting for Effective Virtual Screening at Protein Interaction Sites.Host-rabies virus protein-protein interactions as druggable antiviral targetsStructural properties of non-traditional drug targets present new challenges for virtual screening.Therapeutic opportunities within the DNA damage response.Disulfide-mediated stabilization of the IκB kinase binding domain of NF-κB essential modulator (NEMO).Can We Rely on Computational Predictions To Correctly Identify Ligand Binding Sites on Novel Protein Drug Targets? Assessment of Binding Site Prediction Methods and a Protocol for Validation of Predicted Binding Sites.Nanocaged platforms: modification, drug delivery and nanotoxicity. Opening synthetic cages to release the tiger.Identifying druggable targets by protein microenvironments matching: application to transcription factorsDruggability analysis and structural classification of bromodomain acetyl-lysine binding sitesDrug-Like Protein-Protein Interaction Modulators: Challenges and Opportunities for Drug Discovery and Chemical Biology.Tapping the RNA world for therapeutics.Mapping the 3D structures of small molecule binding sites.Computer-Aided Drug Design in Epigenetics.Systematic interrogation of diverse Omic data reveals interpretable, robust, and generalizable transcriptomic features of clinically successful therapeutic targets.Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future.P2Rank: machine learning based tool for rapid and accurate prediction of ligand binding sites from protein structureComputational Methods to Support Fragment-based Drug Discovery
P2860
Q26773093-A1044418-2B11-41EA-A135-4BF77AA6F1D1Q26997089-EA7E2C18-E8BC-4810-AD95-95C1B5A8292AQ27008706-3B439CF8-6738-4983-A3BA-6A9AD7CC7990Q27674729-72029782-6553-4320-B4FD-0CEE74305663Q27675760-403E9E7B-FD4B-4A02-AA54-4A354BDF7FEFQ27678891-7F7FAE08-D2BA-491B-8FD5-FEC64C80BFE9Q27681751-34406873-0C7D-4BF9-9C7E-ABFE1F95FA08Q28541379-286BA55B-8304-4B9E-8A3C-5E645271CC13Q28547877-7C743A83-0B84-40B2-9C5B-6481B4EF5142Q30355473-284E3F03-1797-4DDD-8D77-8FF7C31F989FQ30377207-CB9DC4C8-AC95-4BDC-893F-E8F21A988F1DQ30383112-5AD06E1A-4825-476F-A721-CFF8475ED8D7Q33915380-07114129-9620-4F18-B441-1B33FE008580Q34104328-A88BBDB1-9215-44CD-8DC9-971E7F38F6E5Q35236563-226B242C-1805-4E00-91FD-C2738DFCF5C1Q35253755-C590AC70-1585-4BE3-84AA-C650703475F6Q35730955-65F6ED1D-1C3B-4129-A75D-A3ADF202ED86Q35795582-B3C9362F-C33B-435C-BC7C-08F8CA135FC8Q36009999-BF0B50D5-4085-4F92-8CD8-1208152E14C0Q36087937-97B8249E-8AA4-444C-91DD-787150E37C81Q36269125-333643F2-9518-4F04-A728-67C845E89A2EQ36447801-2B07AC02-61F5-4221-B2FF-3B665DBAF6D0Q36673276-27028152-BFE8-4E7B-8D22-6137519C753EQ37284895-D664AA93-C43C-447C-8C7B-754FE9040CB0Q38364665-315ACFD1-0E5E-4C71-BAB2-CBDDD10C89EBQ38940206-035E1F84-BB68-4682-8DC1-6D8434C27757Q38994734-82335558-A248-48BB-95EB-1DBD7067AC3AQ39076542-9B321CBA-97C6-41EC-8826-A55C4374E5BAQ41905622-5570157D-B973-4920-BFCE-C6AFFA51B3E2Q41992499-41DDA85E-69FA-4A2E-A8B5-39AB27640378Q42701435-24F07C58-2AE0-469F-8DBE-1CC965073A92Q52584544-1FDAD400-56FC-4A17-B30D-3265524A0225Q54572862-F9961175-477D-4D47-AD5D-D36214CE7729Q55120002-38F9C74F-3228-4922-AC97-FE52D1083B50Q55155058-DB8F68D4-E022-4D23-BD40-2E8E54812B70Q55364364-C3A099FE-715B-4829-B519-7EC44C4452E9Q57009477-14A47E2D-0CE2-4F35-A6B0-27F300A80E04Q58488998-B0C63A25-6735-44BC-B63F-CA2E1412E5F0
P2860
Structure-based druggability assessment--identifying suitable targets for small molecule therapeutics.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Structure-based druggability a ...... r small molecule therapeutics.
@ast
Structure-based druggability a ...... r small molecule therapeutics.
@en
type
label
Structure-based druggability a ...... r small molecule therapeutics.
@ast
Structure-based druggability a ...... r small molecule therapeutics.
@en
prefLabel
Structure-based druggability a ...... r small molecule therapeutics.
@ast
Structure-based druggability a ...... r small molecule therapeutics.
@en
P2093
P1476
Structure-based druggability a ...... r small molecule therapeutics.
@en
P2093
Brajesh K Rai
Enoch S Huang
Eric B Fauman
P304
P356
10.1016/J.CBPA.2011.05.020
P577
2011-06-23T00:00:00Z